BioXcel Therapeutics, Inc. (BTAI)

0.18USD -74.83% (-0.54)

Over 1M: -77.6%

2026-08-28
Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

0.5 1
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '21 — Operating Income: -26.8M Q4 '21 — Operating Income: -26.1M Q1 '22 — Operating Income: -31.5M Q2 '22 — Operating Income: -36.3M Q3 '22 — Operating Income: -39M Q4 '22 — Operating Income: -52.9M Q1 '23 — Operating Income: -51.2M Q2 '23 — Operating Income: -52.4M Q3 '23 — Operating Income: -48.3M Q4 '23 — Operating Income: -19.9M Q1 '24 — Operating Income: -24.2M Q2 '24 — Operating Income: -17.3M Q3 '24 — Operating Income: -15.3M Q4 '24 — Operating Income: -10.5M Q1 '25 — Operating Income: -10.1M Q2 '25 — Operating Income: -15.9M Q3 '25 — Operating Income: -14.2M Q4 '25 — Operating Income: -10.3M Q1 '26 — Operating Income: -10.2M Q2 '26 — Operating Income: -10.2M -45M -30M -15M 0
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Operating Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 62 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.7
SBC / sales 245.8%
ROIC -44.0%
Accruals -69.3%
Gross margin 53.1%
Asset turnover 0.026×
ROA -246.1%
Capex / sales —
EBITDA margin —
FCF margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
ROCE —
ROE —

2 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.8
EV/Sales 271.9×
EV/OE -3.8×
P/C 0.44×
FCF yield -896.4%
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/B —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

1.2
ND/EBITDA -0.97
Current ratio 0.21×
Cash / Debt 0.061×
F-score 3.0 pts
Quick ratio 0.21×
Cash runway —
Debt / Eq —
Debt payback —
Equity / Assets —
Net debt / Eq —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

6.2
Sales/sh Y/Y -82.3%
Sales Q/Q +51.7%
Shares change +382.1%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

3 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.